BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33462822)

  • 41. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
    Connors JM; Ansell SM; Fanale M; Park SI; Younes A
    Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
    [No Abstract]   [Full Text] [Related]  

  • 45. Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
    Fujii H; Tsuji T; Sugitani M; Matsumoto Y; Yuba T; Tanaka S; Suga Y; Matsuyama A; Goda S; Omura A; Shiotsu S; Takumi C; Ono S; Hiraoka N
    Curr Probl Cancer; 2021 Dec; 45(6):100739. PubMed ID: 33810911
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
    Bond DA; Dotson E; Awan FT; Baiocchi RA; Blum KA; Maddocks K
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e123-e128. PubMed ID: 30594446
    [No Abstract]   [Full Text] [Related]  

  • 47. Risk-adapted therapy for advanced-stage Hodgkin lymphoma.
    Spinner MA; Advani RH
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):200-206. PubMed ID: 30504311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
    Ogura M; Itoh K; Kinoshita T; Fukuda H; Takenaka T; Ohtsu T; Kagami Y; Tobinai K; Okamoto M; Asaoku H; Sasaki T; Mikuni C; Hirano M; Chou T; Ohnishi K; Ohno H; Nasu K; Okabe K; Ikeda S; Nakamura S; Hotta T; Shimoyama M
    Int J Hematol; 2010 Dec; 92(5):713-24. PubMed ID: 21076995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
    Orellana-Noia VM; Isaac K; Malecek MK; Bartlett NL; Voorhees TJ; Grover NS; Hwang SR; Bennani NN; Hu R; Hill BT; Mou E; Advani RH; Carter J; David KA; Ballard HJ; Svoboda J; Churnetski MC; Magarelli G; Feldman TA; Cohen JB; Evens AM; Portell CA
    Blood Adv; 2021 Sep; 5(18):3623-3632. PubMed ID: 34448831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.
    Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P;
    Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
    Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.
    Dalal M; Gupta J; Price K; Zomas A; Miao H; Ashaye A
    Expert Rev Hematol; 2020 Aug; 13(8):907-922. PubMed ID: 32749937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Cencini E; Fabbri A; Bocchia M
    Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
    [No Abstract]   [Full Text] [Related]  

  • 54. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
    Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
    Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
    Allen PB; Savas H; Evens AM; Advani RH; Palmer B; Pro B; Karmali R; Mou E; Bearden J; Dillehay G; Bayer RA; Eisner RM; Chmiel JS; O'Shea K; Gordon LI; Winter JN
    Blood; 2021 Mar; 137(10):1318-1326. PubMed ID: 32992341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
    Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ABVD plus rituximab
    Strati P; Fanale MA; Oki Y; Turturro F; Fayad LE; Bartlett NL; Gladstone DE; Kasamon YL; Portlock CS; Wilson WH; Goy A; Younes A; Lee HJ
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract]   [Full Text] [Related]  

  • 59. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
    Graczyk J; Cheung MC; Buckstein R; Chan K
    Leuk Lymphoma; 2014 Jan; 55(1):56-62. PubMed ID: 23597142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sequencing therapies in Hodgkin lymphoma.
    Phillips EH; Collins GP; Cwynarski K
    Lancet Haematol; 2021 Aug; 8(8):e537-e539. PubMed ID: 34329571
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.